|
|
|
| home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA) |
|
|
 WHITE PAPERS |
|
PRA Health Sciences (PRA)
|
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
|
|
Governments, healthcare payers, and social and health reforms, combined
with the increased incidence of conditions such as cancer and diabetes
are paving the way for increased uptake of biologic medicines in
emerging markets. However, expensive biologic medicines can be
prohibitive to many patients, creating a high level of unmet clinical
need. At its best, the global expansion of biosimilars can mean a robust
and steady supply of existing and new drugs reaching far-flung patient
populations, but localized biosimilar drug developments, especially in
China and India, combined with a lack of robust pharmacovigilance
systems, threaten to derail the industry by putting patient health at
risk.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Quanterix to Launch High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection
Quanterix Corporation, a company dedicated to digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it will be expanding its single molecule array, or Simoa, technology platform portfolio to include the new Quanterix SR-Plex benchtop instrument. In the same way that the fully automated HD-1 Analyzer offers detection and measurement of biomarkers with unprecedented sensitivity, the SR-Plex will use single molecule measurements to assess previously undetectable proteins and can significantly reduce sample volume requirements when compared to alternative approaches, all in a benchtop format that can be easily integrated with existing automation platforms. The first unveiling of the SR-Plex will happen today at the Next Generation Dx Summit in Washington, D.C.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
Synergy Research Group
In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >> |
|
 |
Industry Events |
 |
7th annual Orphan Drugs and Rare Diseases UK
18-19 October 2017, Holiday Inn Kensington Forum, London
SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >> |
|
|
|
